GSA Capital Partners LLP Has $731,000 Stock Position in Rocket Pharmaceuticals, Inc. $RCKT

GSA Capital Partners LLP grew its stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 502.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 224,276 shares of the biotechnology company’s stock after acquiring an additional 187,037 shares during the period. GSA Capital Partners LLP owned 0.21% of Rocket Pharmaceuticals worth $731,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Prudential Financial Inc. bought a new position in shares of Rocket Pharmaceuticals during the second quarter worth approximately $25,000. CANADA LIFE ASSURANCE Co grew its holdings in Rocket Pharmaceuticals by 94.4% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 12,202 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 5,926 shares in the last quarter. Corton Capital Inc. bought a new position in Rocket Pharmaceuticals during the 2nd quarter worth $38,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Rocket Pharmaceuticals during the second quarter worth $43,000. Finally, Savant Capital LLC bought a new stake in shares of Rocket Pharmaceuticals in the second quarter valued at about $46,000. Institutional investors own 98.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on RCKT shares. Morgan Stanley set a $5.00 price objective on shares of Rocket Pharmaceuticals in a research note on Thursday, January 8th. Bank of America dropped their price target on shares of Rocket Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. TD Cowen upgraded Rocket Pharmaceuticals to a “hold” rating in a research note on Friday, December 19th. JPMorgan Chase & Co. downgraded Rocket Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research report on Tuesday, November 18th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $16.00 price objective on shares of Rocket Pharmaceuticals in a report on Friday, November 7th. Eight investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, Rocket Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $14.36.

Insider Buying and Selling at Rocket Pharmaceuticals

In other Rocket Pharmaceuticals news, General Counsel Martin Wilson sold 12,253 shares of Rocket Pharmaceuticals stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $3.31, for a total value of $40,557.43. Following the transaction, the general counsel owned 683,376 shares in the company, valued at $2,261,974.56. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Gaurav Shah sold 12,279 shares of the stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $3.31, for a total transaction of $40,643.49. Following the completion of the transaction, the chief executive officer directly owned 1,052,045 shares of the company’s stock, valued at $3,482,268.95. This trade represents a 1.15% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 29,415 shares of company stock valued at $97,398. 24.76% of the stock is owned by corporate insiders.

Rocket Pharmaceuticals Stock Up 1.1%

Shares of RCKT opened at $3.78 on Friday. Rocket Pharmaceuticals, Inc. has a one year low of $2.19 and a one year high of $11.08. The company has a market cap of $409.07 million, a P/E ratio of -1.68 and a beta of 0.48. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.30 and a quick ratio of 7.30. The firm has a 50 day simple moving average of $3.51 and a two-hundred day simple moving average of $3.40.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.